Cancer Vaccine in Phase II Trial
Hørsholm - Danish Pharmexa A/S will initiate the first phase II trial with its HER-2 Protein AutoVac™ breast cancer vaccine. The trial including up to 50 breast cancer patients will start in Hungary, followed by Poland within a few weeks, and is expected to be concluded by mid-2006. An additional phase II trial with the vaccine formulated in a stronger immuno-stimulatory adjuvant is under preparation to be concluded in late 2006. The vaccine has been designed to generate an antibody response against the HER-2 protein, over-expressed in many cancers including breast cancers.